p53 expression in repair/reactive renal tubular cells: A potential pitfall leading to a false-positive diagnosis of urine cytology.
glomerular disease
immunocytochemistry
p53
renal tubular cell
urine cytology
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
07
09
2021
received:
17
07
2021
accepted:
13
09
2021
pubmed:
17
11
2021
medline:
18
3
2022
entrez:
16
11
2021
Statut:
ppublish
Résumé
p53 immunostaining is routinely used as a surrogate marker for TP53 mutational status. In urine cytology, p53 immunocytochemistry is reportedly useful in detecting urothelial carcinoma cells as well as in improving the detection sensitivity and specificity. However, to the best of our knowledge, p53 expression in repair/reactive renal tubular cells (RRTCs) from urine cytologic specimens has not been assessed to date. We evaluated the immunoexpression of p53 and homogentisate 1,2-dioxygenase (HGD) antibody, a renal tubular cells marker, in RRTCs using voided urine and renal biopsy samples from 80 patients who were histologically diagnosed with glomerular disease. Repair/reactive renal tubular cells were detected in 68 (68/80, 85%) samples at a mean count of 141.1 cells per sample (range, 5-4220). Immunocytochemical analysis found p53-positive RRTCs in all the samples (68/68, 100%) with an average p53 positivity rate of RRTCs per sample at 47.7% (range, 3.8%-96.5%). Of the 68 p53-positive RRTC samples, 38 (55.9%) included cells that were HGD positive for cytoplasm. Similarly, renal biopsy analysis revealed p53-positive RRTCs in all the specimens (68/68, 100%). All 68 (100%) cases showed RRTCs that were positive for both p53 and HGD. To avoid false positives of p53 immunocytochemistry, cytologists must consider the fact that RRTCs from patients with glomerular disease are positive for p53.
Sections du résumé
BACKGROUND
p53 immunostaining is routinely used as a surrogate marker for TP53 mutational status. In urine cytology, p53 immunocytochemistry is reportedly useful in detecting urothelial carcinoma cells as well as in improving the detection sensitivity and specificity. However, to the best of our knowledge, p53 expression in repair/reactive renal tubular cells (RRTCs) from urine cytologic specimens has not been assessed to date.
METHODS
We evaluated the immunoexpression of p53 and homogentisate 1,2-dioxygenase (HGD) antibody, a renal tubular cells marker, in RRTCs using voided urine and renal biopsy samples from 80 patients who were histologically diagnosed with glomerular disease.
RESULTS
Repair/reactive renal tubular cells were detected in 68 (68/80, 85%) samples at a mean count of 141.1 cells per sample (range, 5-4220). Immunocytochemical analysis found p53-positive RRTCs in all the samples (68/68, 100%) with an average p53 positivity rate of RRTCs per sample at 47.7% (range, 3.8%-96.5%). Of the 68 p53-positive RRTC samples, 38 (55.9%) included cells that were HGD positive for cytoplasm. Similarly, renal biopsy analysis revealed p53-positive RRTCs in all the specimens (68/68, 100%). All 68 (100%) cases showed RRTCs that were positive for both p53 and HGD.
CONCLUSION
To avoid false positives of p53 immunocytochemistry, cytologists must consider the fact that RRTCs from patients with glomerular disease are positive for p53.
Identifiants
pubmed: 34783171
doi: 10.1002/cam4.4389
pmc: PMC8683536
doi:
Substances chimiques
Biomarkers, Tumor
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8846-8853Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cytopathology. 2017 Dec;28(6):524-530
pubmed: 28913845
Cytopathology. 2017 Apr;28(2):96-102
pubmed: 27859848
Cytopathology. 2009 Aug;20(4):224-30
pubmed: 19563449
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Cancer Res. 2002 Jan;8(1):171-9
pubmed: 11801555
Histopathology. 2017 Aug;71(2):296-304
pubmed: 28342221
Cytopathology. 2021 Sep;32(5):654-659
pubmed: 34033150
Cancer. 2014 Dec 1;120 Suppl 23:3815-25
pubmed: 25412393
Cytopathology. 2010 Oct;21(5):326-33
pubmed: 20105211
Cytojournal. 2020 Feb 27;17:3
pubmed: 32256669
Diagn Cytopathol. 2004 Nov;31(5):342-6
pubmed: 15468128
Eur Urol. 2005 Jun;47(6):736-48
pubmed: 15925067
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cytopathology. 2011 Aug;22(4):247-52
pubmed: 20653719
Br J Cancer. 2005 Jul 25;93(2):242-7
pubmed: 15999101
J Am Soc Nephrol. 2004 Jul;15(7):1826-34
pubmed: 15213270
Mol Cell Biol. 2002 Sep;22(17):6170-82
pubmed: 12167711
Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):225-9
pubmed: 15551735
Am J Physiol Cell Physiol. 2011 Nov;301(5):C1201-12
pubmed: 21832251
Nat Rev Cancer. 2004 Oct;4(10):793-805
pubmed: 15510160
Am J Physiol Cell Physiol. 2010 Nov;299(5):C1110-7
pubmed: 20720180
Cancer Med. 2021 Dec;10(24):8846-8853
pubmed: 34783171
Hum Pathol. 2011 Apr;42(4):455-81
pubmed: 21106220
Acta Cytol. 2008 May-Jun;52(3):297-303
pubmed: 18540293
Cancer. 2001 Jun 1;91(11):2127-35
pubmed: 11391594
Diagn Cytopathol. 2017 Feb;45(2):85-90
pubmed: 27888661
Diagn Mol Pathol. 2004 Dec;13(4):217-23
pubmed: 15538112
Am J Surg Pathol. 2001 Aug;25(8):1074-8
pubmed: 11474293
J Am Soc Nephrol. 2014 Oct;25(10):2278-89
pubmed: 24700871
J Clin Oncol. 2004 Mar 15;22(6):1007-13
pubmed: 14981105
Cytopathology. 2016 Dec;27(6):456-464
pubmed: 27873391